This program was co-developed by the Canadian Ophthalmological Society and the Canadian Retina Society in order to achieve scientific integrity, objectivity and balance as per the RCPSC’s accreditation guidelines.
OUR SPONSORS

The Canadian Retina Society and the Canadian Ophthalmological Society gratefully acknowledge the participation of the following corporate sponsors, each of whom has provided an unrestricted educational grant in support of the meeting program.

GOLD SPONSORS

Alcon

Bayer

Novartis Pharmaceuticals

Science For A Better Life

SILVER SPONSORS

Allergan

Bausch + Lomb

BRONZE SPONSORS

Innova

LabTician

Ophtalmic Freight

Medical Pharmacies

Salient

FRIENDS

The Foundation Fighting Blindness

The Retina Foundation of Canada
# TABLE OF CONTENTS

Welcome .................................................................................................................. 2

General Information .................................................................................................. 3

Guest Speakers ........................................................................................................... 4

Dr. Mila Oh Memorial Lecture .................................................................................. 6

Scientific Program ..................................................................................................... 7

  Thursday .................................................................................................................. 7

  Friday ...................................................................................................................... 7

  Saturday .................................................................................................................. 8

  Sunday ..................................................................................................................... 9

Co-developed Accredited Symposia ......................................................................... 10

Disclosures ................................................................................................................ 11

Sponsors ..................................................................................................................... 12

Program at a Glance .................................................................................................. Back Cover
Dear Delegates, Guest Speakers and Sponsors,

It is with great pleasure that we welcome you to our 3rd Annual Canadian Retina Society Meeting – our yearly opportunity to come together to learn from each other.

We have created an exceptional scientific program delivered by our outstanding guest speakers from Europe, the US and Canada. We have an excellent balance of both medical and surgical topics, and this year’s schedule will allow you to optimize your learning, social and adventure experiences – all in the spectacular setting of North America’s finest mountain resort.

New this year is the presentation of the results of our first-ever, made-in-Canada “Canadian Preference and Trends (CAN-PAT) Survey.” We look forward to sharing these data with you, as they provide a fascinating glimpse into our daily choices in the clinic and OR.

If you are a CRS member, we hope you’ll join us for our CRS Business Meeting. The CRS Executive are busy all year supporting the needs of our members – come and learn what we’ve been working on!

We could not mount this meeting without the very generous support of our sponsors – we value our partnerships with each and every one. Please take the time to speak to their representatives. We also thank the staff of the Canadian Ophthalmological Society for their attention to the many behind-the-scenes details that allow this meeting to run smoothly.

We rely on your feedback to ensure that this meeting and future meetings meet your expectations. Please take the time to complete the evaluations and, of course, feel free to speak to any of us or the onsite staff.

Thank you for coming to Whistler – we wish you a wonderful meeting, great skiing and safe travels!

Sincerely,

Jim Whelan, MD, FRCSC
Matt Tennant, MD, FRCSC
Netan Choudhry, MD, FRCSC

President, CRS
Co-chair, CPD Director
Co-chair
GENERAL INFORMATION

REGISTRATION
The Registration Desk is located in the Frontenac Foyer
Thursday, February 26  1600-1900
Friday, February 27   0600-1030  1500-1830
Saturday, February 28 0600-1030  1500-1830
Sunday, March 1      0630-1000

BREAKFAST AND REFRESHMENTS
All breakfasts and refreshment breaks will be served in Frontenac BC.

SCIENTIFIC SESSIONS
All scientific sessions and the CRS Business Meeting will be held in Frontenac A.

SPEAKER INFORMATION
Guest speakers may visit the audio-visual technician for assistance with their presentations.
Note: All speakers are kindly asked to upload their final slides at least one hour prior to their presentation time slot.

LEARNING OBJECTIVES
• Describe the identification and treatment of both common and rare medical and surgical diseases of the retina
• Describe the testing and treatment recommendations for patients with retinoblastoma
• Describe the current practice patterns of Canadian retina specialists

CPD CREDITS
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 16 Section 1 credits.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at Earning credit for participation in international activities.

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, February 26, 2015</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Friday, February 27, 2015</td>
<td>6.0</td>
<td></td>
</tr>
<tr>
<td>Saturday, February 28, 2015</td>
<td>6.0</td>
<td></td>
</tr>
<tr>
<td>Sunday, March 1, 2015</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>Total hours earned</td>
<td>16.0</td>
<td></td>
</tr>
</tbody>
</table>

Physicians should only claim credits commensurate with the extent of their participation in the activity.

EVALUATION
Evaluation is a required component the RCPSC’s MOC program. Please complete the evaluation for each session you attend in order to claim your CPD credits. The online evaluation is available at http://crs2015.ca. Please complete this evaluation by March 31, 2015. Evaluation stations are available in Frontenac A.

We’ve Gone Mobile!
For detailed program information, scan the QR code or visit Eventmobi.com/2015crs.
The free CRS meeting app can be viewed on any mobile device or computer.
GUEST SPEAKERS

Alice Y.Y. Cheng, MD, FRCPC
Endocrinologist, Trillium Health Partners and St. Michael’s Hospital
Assistant Professor, Department of Medicine, University of Toronto

Allen C. Ho, MD
Director of Retina Research, Wills Eye Hospital
Professor of Ophthalmology, Thomas Jefferson University School of Medicine

Dean Elliott, MD
Associate Director, Retina Service
Stelios Evangelos Gragoudas Associate Professor of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School

Peter J. Lin, MD, CCFP
Director Primary Care Initiatives, Canadian Heart Research Centre

Brenda L. Gallie, MD, FRCSC, CM, OOnt
Director, Retinoblastoma Program, SickKids Hospital, Toronto
Adjunct Scientist and Staff, Ocular Oncology Clinic, Princess Margaret Cancer Centre

Theodor Stappler, MD
Consultant vitreoretinal surgeon and clinical lead in surgical retina
St Paul’s Eye Unit, Royal Liverpool University Hospital

Professor
Dr. Florian Gekeler
Chair, Department of Ophthalmology Stuttgart Hospital
Foundation Fighting Blindness

The Foundation Fighting Blindness is restoring hope and sight. Ophthalmologists like you play a key role in our mission to lead this fight against blindness by advancing retinal disease research, education and public awareness. As Canada’s largest charity for sight-saving research, we have invested over $28 million at universities and hospitals across the country, and created a national patient registry to further enable clinical research. We also offer a life-changing educational experience for your patients and their families at our annual Vision Quest conference, held in cities across Canada.

“As the co-chairs of Vision Quest 2014 in Calgary, we witnessed how eager our patients were to be more engaged with their care. In fact, community interest was so high, we’ve volunteered to host another Vision Quest meeting in 2015. Working with the Foundation Fighting Blindness inspires hope that we can change the future of eye health together.”

– Geoff Williams, MD, FRCSC; Amin Kherani, MD, FRCSC

Help us restore hope and sight. Visit ffb.ca or call 1.800.461.3331.

Sharon Colle, President & CEO
Foundation Fighting Blindness
DR. MILA OH MEMORIAL LECTURE

Saturday, February 28, 2015
1600-1650

One Retinoblastoma World: A consortium for optimized care everywhere
Brenda L. Gallie, MD, FRCSC, CM, OOnt

It is with great pride that we present the Dr. Mila Oh Memorial Lecture. In 1995, Mila was accepted as a resident in the Department of Ophthalmology at McGill University. From that year on, she was considered a star. She was intelligent, hardworking, and had a great sense of humour. Mila was Chief Resident in 1999 before heading to Duke University to pursue vitreoretinal fellowship studies for the next two years. Upon her return to Montreal, Mila worked diligently at the Royal Victoria Hospital in Montreal. She brought passion, commitment and firm opinions to the management of patients, to the training of young ophthalmologists and the betterment of her department. While battling cancer, Mila assumed the role of Interim Program Director, offering her time to relieve a colleague who was also fighting cancer. Mila was also a member of the COS clinical practice guideline committee on diabetic retinopathy. Tragically, she died before the guidelines were completed. The final published guidelines were dedicated to her memory. To those who were blessed to work with Mila, there was no better example of devotion, and no better example of a team player. She was a very dear friend and is greatly missed by her family, patients and colleagues.

With thanks to Dr. Oh’s husband Ken Hunt for the photo of Mila, and her colleagues Drs. Miguel Burnier, Jean Deschénes and Michael Kapusta for sharing their memories.

We are honoured to welcome Dr. Brenda Gallie to present this lecture. For 40 years, Dr. Gallie and her research teams have focused on optimizing care for retinoblastoma; learning fundamental principles of cancer, genetics and translational medicine from this rare disease. Retinoblastoma research has led to the recognition that cancer is a genetic disease; showed how to find tumor suppressor genes; illustrated the role of progressive genomic instability from normal to cancer; and developed top-quality molecular diagnostics in a business model with the patient foremost. For optimal care and outcomes, they developed the first ever national guidelines for care for Canada, now adopted in Kenya. With worldwide stakeholders, including retinoblastoma survivors, One Retinoblastoma World (1RBW) has emerged with a constellation model of collaborative governance that supports multi-organization partnerships and inspires innovative thinking and problem solving.

We thank The Retina Foundation of Canada for their generous support of this lecture.
SCIENTIFIC PROGRAM

Thursday, February 26, 2015

1200-1600 Arrivals
Industry advisory boards

1620-1625 Welcome – Jim Whelan and Matt Tennant

1625-1725 Scientific session #1
At the end of this session, participants will be able to:
• Understand how to identify the presentations of a variety of unusual retinal pathologies
• Know what special tests should be performed to confirm the diagnosis for rare retinal diseases
• Recognize the imaging features associated with retinal disease

1625-1725 Mystery cases – Moderator: Netan Choudhry

1730-1900 CRS Business Meeting

1900-2030 Welcome Reception
Portobello Restaurant, Fairmont Chateau Whistler
Please join us for a glass (or two) of Whistler’s finest micro-brewery beer or select wine, to welcome colleagues and friends to this year’s meeting.

Friday, February 27, 2015

0600-0630 Breakfast

0630-0900 Scientific session #2
At the end of this session, participants will be able to:
• Gain familiarity with the presentation, diagnosis, and management of vitreoretinal lymphoma
• Understand new and potential treatments for diabetic retinopathy
• Review pathological and imaging features of eyes with unique response to selected anti-VEGF therapy

0630 Welcome and introductions – Matt Tennant

0635 Vitreoretinal lymphoma – Dean Elliott

0655 Q & A

0705 Diabetic retinopathy: current and investigational therapies – Allen C. Ho

0730 Q & A

0740 Anti-VEGF switch cases – Moderator: Netan Choudhry; Panelists: Allen C. Ho, Dean Elliott

0900 Refreshment break

0910-1010 Co-developed accredited symposium: Multidisciplinary care of diabetic macular edema
At the end of this session, participants will be able to:
• Understand the most recent clinical trial data for anti-VEGF medication in the treatment of DME
• Identify the gaps in care for patients with DME and create tools to help bridge these gaps
• Engage multiple stakeholders to improve the diagnosis and treatment of DME
• Better leverage the key roles played by family physicians, endocrinologists and ophthalmologists in the management of DME
• Describe the multifactorial approach to diabetes management as outlined in the Canadian Diabetes Association 2013 clinical practice guidelines

0910 Welcome and introductions – Geoff Williams

0920 DME trials – David Maberley

0930 Diabetes 101 – Alice Y.Y. Cheng

0940 DME – Bridging the gaps – Peter J. Lin

0950 Panel discussion – Ask the ophthalmologist / endocrinologist / family doctor – Panelists: David Maberley, Alice Y.Y. Cheng, Peter J. Lin

* This session was co-developed by the Canadian Ophthalmological Society and Bayer and was planned to achieve scientific integrity, objectivity and balance.

1010 Adjourn
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1530-1600</td>
<td>Refreshment break</td>
</tr>
<tr>
<td>1600-1830</td>
<td>Scientific session #3</td>
</tr>
<tr>
<td></td>
<td>At the end of this session, participants will be able to:</td>
</tr>
<tr>
<td></td>
<td>• Understand basic principles and controversial topics in the management of open globe injuries</td>
</tr>
<tr>
<td></td>
<td>• Understand the risk factors, findings, and surgical management of retinal detachment due to proliferative vitreoretinopathy</td>
</tr>
<tr>
<td></td>
<td>• Raise awareness of an individualized management of ocular trauma</td>
</tr>
<tr>
<td></td>
<td>• Understand how tamponades work and their advantages and limitations</td>
</tr>
<tr>
<td></td>
<td>• Become more knowledgeable about current treatment options for complex retinal detachments</td>
</tr>
<tr>
<td>1600</td>
<td>Introduction – Jim Whelan</td>
</tr>
<tr>
<td>1605</td>
<td>Ocular management of trauma – Dean Elliott</td>
</tr>
<tr>
<td>1625</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>1635</td>
<td>Medical management of PVR – Dean Elliot</td>
</tr>
<tr>
<td>1655</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>1705</td>
<td>An individualized approach to post-traumatic exploratory vitrectomy in children and young adults – Theodor Stappler</td>
</tr>
<tr>
<td>1725</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>1735</td>
<td>Molecular design for novel ocular tamponades – Theodor Stappler</td>
</tr>
<tr>
<td>1800</td>
<td>Panel discussion: Management of complex retinal detachment – Panelists: Theodor Stappler, Dean Elliott, Matt Tennant, Jim Whelan, Netan Choudhry</td>
</tr>
<tr>
<td>1830</td>
<td>Adjourn</td>
</tr>
<tr>
<td>1900-2200</td>
<td>Dinner</td>
</tr>
<tr>
<td></td>
<td>Grand Hall, Squamish Lil’wat Cultural Centre</td>
</tr>
<tr>
<td></td>
<td>Located only a 2-minute walk from the Fairmont Chateau</td>
</tr>
<tr>
<td></td>
<td>Whistler, this historic venue offers you the opportunity to explore featured exhibits and the creative works of the artists in residence while you enjoy a reception-style dinner.</td>
</tr>
</tbody>
</table>

**Saturday, February 28, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0600-0630</td>
<td>Breakfast</td>
</tr>
<tr>
<td>0630-0900</td>
<td>Scientific session #4</td>
</tr>
<tr>
<td></td>
<td>At the end of this session, participants will be able to:</td>
</tr>
<tr>
<td></td>
<td>• Review current investigational cell therapy approaches for age-related macular degeneration</td>
</tr>
<tr>
<td></td>
<td>• Understand the benefits and detractions of stem cell implantation for geographic atrophy</td>
</tr>
<tr>
<td></td>
<td>• Discuss the evidence for and current experience with a visual prosthesis system for severe retinal degeneration</td>
</tr>
<tr>
<td></td>
<td>• Understand the specifics of subretinal vs. epiretinal implants and its specific surgical challenges</td>
</tr>
<tr>
<td></td>
<td>• Develop an overview over currently achievable results with electronic visual implants</td>
</tr>
<tr>
<td></td>
<td>• Have and in-depth knowledge of how exactly the anatomical structures are affected by modern surgical and pharmacological intervention</td>
</tr>
<tr>
<td>0630</td>
<td>Welcome and introductions – Jim Whelan</td>
</tr>
<tr>
<td>0635</td>
<td>Cell therapy for age-related macular degeneration – Allen C. Ho</td>
</tr>
<tr>
<td>0700</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>0710</td>
<td>The Argus® II Retinal Prosthesis for severe retinitis pigmentosa – Allen C. Ho</td>
</tr>
<tr>
<td>0735</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>0745</td>
<td>Subretinal implants: surgical challenges and visual outcomes – Florian Gekeler</td>
</tr>
<tr>
<td>0810</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>0820</td>
<td>Surgical and pharmacological effects on the vitreoretinal interface – Theodor Stappler</td>
</tr>
<tr>
<td>0845</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>0900</td>
<td>Refreshment break</td>
</tr>
<tr>
<td>0910-1010</td>
<td>Co-developed accredited symposium: Management of macular holes 2015</td>
</tr>
<tr>
<td></td>
<td>At the end of this session, participants will be able to:</td>
</tr>
<tr>
<td></td>
<td>• Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies</td>
</tr>
<tr>
<td></td>
<td>• Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions</td>
</tr>
</tbody>
</table>
• Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
• Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
• Optimize the management of macular holes in difficult-to-treat patients

0910  Macular holes: review of recent literature  
       – Netan Choudhry

0920  OCT reading: identifying and measuring macular holes  – Allen C. Ho

0935  Panel discussion based on macular hole management  
       – Moderators: David Chow and Michael Kapusta

* This session was co-developed by the Canadian Ophthalmological Society and Alcon and was planned to achieve scientific integrity, objectivity and balance.

1010  Adjourn

1530-1600  Refreshment break

1600-1830  Scientific session #5
At the end of this session, participants will be able to:
• Understand that retinoblastoma is the same disease, everywhere and that successful care for retinoblastoma depends on early diagnosis, expertise and realistic plans for the newly diagnosed child, and global networking
• Understand that the whole child with retinoblastoma is more important than the eye
• Appreciate that clinical trials are difficult in rare diseases, but may be replaced by a learning health system
• Understand the benefits and harms of innovation using the analysis of the Gartner Hype Cycle as illustration, and how formal research fails children
• Know the mechanisms leading to different types of cataracts post-vitrectomy
• Understand the impact of high-altitude medicine to general physiology and the eye

1600  Introductions  
       – Matt Tennant and John Galic, President, The Retina Foundation of Canada

1605  Dr. Mila Oh Memorial Lecture: One Retinoblastoma World: A consortium for optimized care everywhere  
       – Brenda L. Gallie

1655  The desperate need for evidence in quality care for retinoblastoma  
       – Brenda L. Gallie

1720  Q & A

1730  Why is there cataract after vitrectomy?  
       – Florian Gekeler

1750  Q & A

1800  High-altitude ophthalmology  
       – Florian Gekeler

1820  Q & A

1830  Adjourn

1900-2000  Ice Bar  
          Portobello Restaurant Patio, Fairmont Chateau Whistler  
          Please join us for a drink and a chat with colleagues and friends.

Sunday, March 1, 2015

0630-0700  Breakfast

0700  Introduction  – Jim Whelan

0705  The Foundation Fighting Blindness  
       – Ann Morrison, Director of Philanthropy

0710-1000  Scientific session #6
At the end of this session, participants will be able to:
• Understand the current treatment patterns of retina specialists across Canada
• Review unique surgical management techniques for vitreoretinal diseases

0710  Expanding the Dialogue: Results of the Canadian Preferences and Trends (CAN-PAT) Survey  
       – Jim Whelan and Netan Choudhry

0755  Q & A

0810  Interesting surgical cases  
       Panelists: Matt Tennant, Netan Choudhry

1000  Adjourn
Co-Developed Accredited Symposium
Friday, February 27, 2015 | 0910-1010

Multidisciplinary Care of Diabetic Macular Edema

SCIENTIFIC PLANNING COMMITTEE
Dr. Geoff Williams, Chair
Dr. Matt Tennant
Dr. David Maberley
Dr. Amin Kherani, COS representative

ACCREDITATION STATEMENT: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 1 Section 1 credits. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at http://www.ama-assn.org/ama/pub/education-careers/continuing-medical-education/physicians-recognition-award-credit-system/other-ways-earn-ama-pra-category/international-programs.page.

This symposium was co-developed with Bayer and was planned to achieve scientific integrity, objectivity and balance. The use of the partner logo is ethically permissible.

Light snacks and refreshments will be served.

Learning Objectives
At the end of this session, participants will be able to:

• Understand the most up-to-date clinical trial data for anti-VEGF use in the treatment of DME
• Describe the multifactorial approach to diabetes management as outlined in the Canadian Diabetes Association 2013 clinical practice guidelines
• Identify the gaps in care for patients with DME and create tools to help bridge these gaps
• Engage multiple stakeholders to improve the diagnosis and treatment of DME
• Better leverage the key roles played by family physicians, endocrinologists and ophthalmologists in the management of DME

0910 Welcome and introductions – Geoff Williams
0920 DME trials – David Maberley
0930 Diabetes 101 – Alice Y.Y. Cheng
0940 DME – Bridging the gaps – Peter J. Lin
0950 Panel discussion – Ask the ophthalmologist/endocrinologist/family doctor

0910 Macular holes: Review of recent literature – Netan Choudhry
0925 OCT reading: Identifying and measuring macular holes – Allen Ho
0935 Panel discussion based on macular hole management – Moderators: David Chow and Michael Kapusta

Light snacks and refreshments will be served.

Learning Objectives
At the end of this session, participants will be able to:

• Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies
• Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions
• Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
• Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
• Optimize the management of macular holes in difficult-to-treat patients

0910 Welcome and introductions – Geoff Williams
0920 DME trials – David Maberley
0930 Diabetes 101 – Alice Y.Y. Cheng
0940 DME – Bridging the gaps – Peter J. Lin
0950 Panel discussion – Ask the ophthalmologist/endocrinologist/family doctor

0910 Macular holes: Review of recent literature – Netan Choudhry
0925 OCT reading: Identifying and measuring macular holes – Allen Ho
0935 Panel discussion based on macular hole management – Moderators: David Chow and Michael Kapusta

Light snacks and refreshments will be served.

Learning Objectives
At the end of this session, participants will be able to:

• Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies
• Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions
• Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
• Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
• Optimize the management of macular holes in difficult-to-treat patients

0910 Welcome and introductions – Geoff Williams
0920 DME trials – David Maberley
0930 Diabetes 101 – Alice Y.Y. Cheng
0940 DME – Bridging the gaps – Peter J. Lin
0950 Panel discussion – Ask the ophthalmologist/endocrinologist/family doctor

0910 Macular holes: Review of recent literature – Netan Choudhry
0925 OCT reading: Identifying and measuring macular holes – Allen Ho
0935 Panel discussion based on macular hole management – Moderators: David Chow and Michael Kapusta

Light snacks and refreshments will be served.

Learning Objectives
At the end of this session, participants will be able to:

• Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies
• Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions
• Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
• Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
• Optimize the management of macular holes in difficult-to-treat patients

0910 Welcome and introductions – Geoff Williams
0920 DME trials – David Maberley
0930 Diabetes 101 – Alice Y.Y. Cheng
0940 DME – Bridging the gaps – Peter J. Lin
0950 Panel discussion – Ask the ophthalmologist/endocrinologist/family doctor

0910 Macular holes: Review of recent literature – Netan Choudhry
0925 OCT reading: Identifying and measuring macular holes – Allen Ho
0935 Panel discussion based on macular hole management – Moderators: David Chow and Michael Kapusta

Light snacks and refreshments will be served.

Learning Objectives
At the end of this session, participants will be able to:

• Discuss recent advances in the management of macular holes involving the use of ocriplasmin, surgical techniques, and imaging technologies
• Classify macular holes using the OCT-based anatomic classification system and leverage this information when making treatment decisions
• Identify patient baseline characteristics, such as macular hole size and presence of VMT, that affect treatment decisions
• Assess the benefits and risks of surgical techniques, such as ILM peeling, when managing macular holes
• Optimize the management of macular holes in difficult-to-treat patients
DISCLOSURES

The scientific planning committee members and guest speakers disclosed the following affiliations (financial or otherwise) with commercial organizations during the past two years. Please note: this information was current at the time of press. Any added information will be available on site.

**CRS Meeting Scientific Planning Committee Members**

**Netan Choudhry**
Grant/research support: Alcon
Consulting and honoraria: Alcon, Optos, Novartis, Allergan, Bayer
Scientific Advisory Board: Alcon, Allergan, Bayer, Novartis, Bausch & Lomb

**Amin Kherani**
Grant/research support: Novartis
Participation in clinical trial: Novartis, Alcon, Bayer, Abbvie, Abbott, Ophthotech
Investments (stock options etc): MD Collaborate
Membership on an advisory panel: Novartis, Bayer, Bausch & Lomb, Allergan, Alcon

**Michael Kapusta**
No affiliation (financial or otherwise) with a commercial organization

**Matthew Tennant**
Grant/research support: Bayer, Novartis
Speaking honoraria: Novartis
Scientific Advisory Board: Bayer

**James Whelan**
Grant/research support: Novartis
Membership on an advisory panel, committee or board of directors: Angiogenesis Foundation

**David Maberley**
Participation in clinical trial: Bayer, Novartis, Ophthotech
Employment/honoraria/consulting fees/in-kind compensation: Abbvie, Alcon, Bayer, Novartis
Membership on an advisory panel, committee or board of directors: Allergan, Alcon

**Geoff Williams**
Grant/research support: Novartis
Participation in clinical trial: Novartis, Bayer
Investments (stock options etc): Arctic Dx, MD Collaborate
Membership on an advisory panel: Bayer, Alcon, Novartis

**Co-developed Accredited Symposia Scientific Planning Committee Members**

**David Chow**
Grant/research support: Bayer, Clarion
Participation in clinical trial: Alcon, Bayer, Novartis
Employment/honoraria/consulting fees/in-kind compensation: Alcon, Novartis, Bayer, Allergan, Synergetics, Katalyst, DORC
Investments (stock options etc): Synergetics, Arctic Dx, Katalyst
Membership on an advisory panel, committee or board of directors: Alcon, Bayer, Katalyst, DORC

**Brad Hinz**
Participation in clinical trial: Bayer, Novartis

**Dean Elliott**
Grant/research support: Ocata, Juvenile Diabetes
Participation in clinical trial: Ocata, Juvenile Diabetes
Consultant: Allmera, Avalanche, Bausch & Lomb, Biogen, ReNeuron, Thrombogenesis
Scientific advisory board: Acucela

**Brenda L. Gallie**
No affiliation (financial or otherwise) with a commercial organization

**Florian Gekeler**
Grant/research support: Retinal Implant, AG
Participation in clinical trial: Retinal Implant, AG
Employment/honoraria/consulting fees/in-kind compensation: Retinal Implant, AG
Investments (stock options etc): Retinal Implant, AG
Membership on an advisory panel, committee or board of directors: Retinal Implant, AG

**Allen C. Ho**
Grant/research support: Alcon, Allergan, Janssen, J&J, Genentec, Regeneron, Thombogenics
Employment/honoraria/consulting fees/in-kind compensation: Alcon, Allergan, Janssen, J&J, Genentec, Regeneron, Thombogenics

**Gerard Williams**
Grant/research support: Alcon, Allergan, Janssen, J&J, Genentec, Regeneron, Thombogenics
Employment/honoraria/consulting fees/in-kind compensation: Alcon, Allergan, Janssen, J&J, Genentec, Regeneron, Thombogenics

**Peter J. Lin**
Employment/honoraria/consulting fees/in-kind compensation: AstraZeneca, Takeda, Boehringer Ingelheim, Eli Lilly, Sanofi, Janssen, Merck, Pfizer, Servier, Abbott, Forest Laboratories, Novartis, Purdue, Allergan

**Theodor Stappler**
Grant/research support: Geuder AG (Germany), Alcon (UK)
Patent holder (research team): Geuder AG (Germany)

LEADING THE WAY IN EYE CARE

Alcon is the global leader in eye care because we are passionate about helping people see better. We are dedicated to enhancing lives by enhancing sight, one of our most precious senses. We provide patients innovative products with the goal to deliver the best patient outcomes. With our three businesses – surgical, pharmaceutical and vision care – we offer the widest spectrum of industry-leading products that address the full life cycle of eye care needs. We are proud of being a trusted partner to professionals across the globe.
Alcon is the global leader in eye care because we are passionate about helping people see better. We are dedicated to enhancing lives by enhancing sight, one of our most precious senses. We provide patients innovative products with the goal to deliver the best patient outcomes. With our three businesses – surgical, pharmaceutical and vision care – we offer the widest spectrum of industry-leading products that address the full life cycle of eye care needs. We are proud of being a trusted partner to professionals across the globe.
You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it.

*Science For a Better Life*. Our commitment is to bring to patients around the world quality medicines for use in diagnosing, combating and preventing disease.

Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with the expertise of innovative partners from science and industry.

Bayer is proud of its commitment and research into diseases of the eye, and supporting groups like the Canadian Retina Society is one great example of Bayer putting its mission of Science For A Better Life into action.

For more information about Bayer, visit www.bayer.ca
Dear Delegate,

On behalf of Bayer Ophthalmology, we hope your meetings in the coming days are insightful, rewarding and inspiring.

Should you have any questions please feel free to reach out to any of our Team who are here in Whistler during the meeting.

We look forward to meeting you over the coming days.

Sincerely,

Taflyn Hornibrook
Bayer Ophthalmology
Novartis Pharmaceuticals Canada Inc. is one of the country’s leading healthcare companies committed to improving the health of Canadians.

We discover and develop medicines that make a real difference.

There can be no delay.

Patients are waiting.
Novartis Group companies employ approximately 130,000 full-time-equivalent associates and sell products in more than 150 countries around the world.

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2013, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. For further information, please consult www.novartis.ca.

Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.

www.novartis.ca
Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential.

Today, we have approximately 10,000 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully.

From our beginnings as an eye care company in 1950, Allergan has a heritage in discovering and developing new therapeutic agents to protect and preserve vision. Eye care professionals and patients rely on Allergan products to treat a variety of eye conditions, including glaucoma, dry eye, and external eye diseases. The Allergan Retina Division introduced retinal specialists to the world’s first biodegradable intravitreal implant and is committed to advancing treatment options for posterior segment diseases with multiple investigational therapies. Allergan is proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. In Canada, Allergan employs more than 200 people and has a corporate head office in Markham, Ontario.
Each day, we have 14 billion little reminders to continue advancing eye health.

From the moment we open our eyes and start to view the possibilities of each new day, we look at how we can improve the well-being of the world’s 14 billion eyes. Will this be the day when one of us unlocks a way to eliminate visual impairment in newborns? Or strikes upon a treatment that actually helps the eye heal itself? To us, these are not some distant hopes. They are the daily questions that add new urgency to all we do and everything we see for the future. We’re Bausch + Lomb, a company solely focused on advancing the vision and care of the world’s eyes.
INNOVA, Canada’s leading distributor of ophthalmic, diagnostic, and surgical instruments is proud to be corporate sponsor of this year’s Canadian Retina Society meeting.

With specialty representatives from coast to coast, and support from our exceptional service team, our customers have confidence in the wide range of products available from INNOVA.

World leaders in technology and instrumentation partner with INNOVA to optimize your diagnosis and management of retinal disease.

D.O.R.C. has over 30 years of experience developing new innovative products setting the standard for retinal surgery.

Heidelberg Engineering’s Spectralis imaging platform provides unparalleled view and accuracy of the retina and retinal vasculature.

NIDEK’s solid-state lasers, and their new VIXI pattern photocoagulator, make laser treatments accurate and easy.

OCULUS’ BIOM and SDI have earned their position as the gold standard for surgical retina observation.

Labtician Ophthalmics, Inc. is a solutions focused provider of specialty innovative medical device and pharmaceutical products to the Canadian Ophthalmic community. We are a world leader in supplying surgical products and accessories for retinal surgery.

Labtician provides the retinal community with reliable service and high quality products from our exclusive commercial partners including Fluoron and Beaver-Visitec International, Inc. Our alliance with Synergetics means Labtician can also offer precision engineered microsurgical instruments, capital equipment and devices primarily for use in vitreoretinal surgery to service the needs of our Canadian retinal surgeons.

Polydor Strouthos
Tel: 905-829-0055
email - pstrouthos@labtician.com
www.labtician.com

Ophthalmic Direct’s service is underpinned by GMD’s strengths in cold chain distribution, customer service, and stakeholder management.

Ophthalmic Direct offers a unique direct distribution channel for specialty ophthalmic products via our partnering network of ophthalmology clinics across Canada.

Through our direct distribution model we ship products directly to ophthalmologist’s offices where we also set up and manage the infrastructure required for proper storage and handling.

Ophthalmic Direct fosters close working relationships with all stakeholders in the process, thereby allowing for seamless care. Our team of dedicated specialists ensures that product supplies are available at clinics when they are needed and also help patients navigate the often cumbersome insurance process needed to obtain coverage.

Our growing presence in Canada positions us uniquely to help our clients to put their product directly into the hands of leading ophthalmologists across the country.

Sally Bibic
Tel: 289-242-8238
email - sbibic@ophthalmicdirect.ca
www.ophthalmicdirect.ca
We are the exclusive Canadian distributor for

Salient Medical Solutions

Is proud to sponsor the 2015 Canadian Retina Society meeting.

www.SalientMed.com
Email: info@salientmed.com
Phone: 855-736-3003

We are the exclusive Canadian distributor for

IRIDEX
CentraSight
AqueSys
Optotek Medical
### PROGRAM AT A GLANCE

#### LEARNING OBJECTIVES

Describe the identification and treatment of both common and rare medical and surgical diseases of the retina

Describe the testing and treatment recommendations for patients with retinoblastoma

Describe the current practice patterns of Canadian retina specialists

---

#### Thursday, February 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1200-1600</td>
<td>Arrivals</td>
</tr>
<tr>
<td></td>
<td>Industry advisory boards</td>
</tr>
<tr>
<td>1620-1725</td>
<td>Scientific session #1</td>
</tr>
<tr>
<td></td>
<td>Mystery cases – Various presenters</td>
</tr>
<tr>
<td>1730-1900</td>
<td>CRS Business Meeting</td>
</tr>
<tr>
<td>1900-2030</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>

---

#### Friday, February 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0600-0630</td>
<td>Breakfast</td>
</tr>
<tr>
<td>0630-0900</td>
<td>Scientific session #2</td>
</tr>
<tr>
<td></td>
<td>Vitreoretinal lymphoma – Dean Elliott</td>
</tr>
<tr>
<td></td>
<td>Diabetic retinopathy: current and investigational therapies – Allen C. Ho</td>
</tr>
<tr>
<td></td>
<td>Anti-VEGF switch cases – Various presenters</td>
</tr>
<tr>
<td>0900</td>
<td>Refreshment break</td>
</tr>
<tr>
<td>0910-1010</td>
<td>Co-developed symposium (Bayer sponsored)</td>
</tr>
<tr>
<td></td>
<td>Multidisciplinary care of diabetic macular edema – David Maberley, Alice Y.Y. Cheng, and Peter J. Lin</td>
</tr>
<tr>
<td>1530-1600</td>
<td>Refreshment break</td>
</tr>
<tr>
<td>1600-1830</td>
<td>Scientific session #3</td>
</tr>
<tr>
<td></td>
<td>Ocular management of trauma – Dean Elliott</td>
</tr>
<tr>
<td></td>
<td>Medical management of PVR – Dean Elliott</td>
</tr>
<tr>
<td></td>
<td>An individualized approach to post-traumatic exploratory vitrectomy in children and young adults – Theodor Stappler</td>
</tr>
<tr>
<td></td>
<td>Molecular design for novel ocular tamponades – Theodor Stappler</td>
</tr>
<tr>
<td></td>
<td>Management of complex retinal detachment: panel discussion</td>
</tr>
<tr>
<td>1900-2200</td>
<td>Dinner</td>
</tr>
</tbody>
</table>

---

#### Saturday, February 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0600-0630</td>
<td>Breakfast</td>
</tr>
<tr>
<td>0630-0900</td>
<td>Scientific session #4</td>
</tr>
<tr>
<td></td>
<td>Cell therapy for age-related macular degeneration – Allen C. Ho</td>
</tr>
<tr>
<td></td>
<td>The Argus® II Retinal Prosthesis for severe retinitis pigmentosa – Allen C. Ho</td>
</tr>
<tr>
<td></td>
<td>Subretinal implants: surgical challenges and visual outcomes – Florian Gekeler</td>
</tr>
<tr>
<td></td>
<td>Surgical and pharmacological effects on the vitreoretinal interface – Theodor Stappler</td>
</tr>
<tr>
<td>0900</td>
<td>Refreshment break</td>
</tr>
<tr>
<td>0910-1010</td>
<td>Co-developed symposium (Alcon sponsored)</td>
</tr>
<tr>
<td></td>
<td>Management of macular holes 2015 – Netan Choudhry, Allen C. Ho, David Chow, Michael Kapusta</td>
</tr>
<tr>
<td>1530-1600</td>
<td>Refreshment break</td>
</tr>
<tr>
<td>1600-1830</td>
<td>Scientific session #5</td>
</tr>
<tr>
<td></td>
<td>Dr. Mila Oh Memorial Lecture: One Retinoblastoma World: a consortium for optimized care everywhere – Brenda L. Gallie</td>
</tr>
<tr>
<td></td>
<td>The desperate need for evidence in quality care for retinoblastoma – Brenda L. Gallie</td>
</tr>
<tr>
<td></td>
<td>Why is there cataract after vitrectomy? – Florian Gekeler</td>
</tr>
<tr>
<td></td>
<td>High-altitude ophthalmology – Florian Gekeler</td>
</tr>
<tr>
<td>1900-2000</td>
<td>Ice Bar</td>
</tr>
</tbody>
</table>

---

#### Sunday, March 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>0630-0700</td>
<td>Breakfast</td>
</tr>
<tr>
<td>0700-1000</td>
<td>Scientific session #6</td>
</tr>
<tr>
<td></td>
<td>Expanding the dialogue Result of the Canadian Preferences and Trends (CAN-PAT) Survey – Jim Whelan and Netan Choudhry</td>
</tr>
<tr>
<td></td>
<td>Interesting surgical cases – Various presenters</td>
</tr>
<tr>
<td>1000</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>